Filing Details

Accession Number:
0001209191-18-004661
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-01-19 21:00:30
Reporting Period:
2018-01-17
Accepted Time:
2018-01-19 21:00:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1594864 Juno Therapeutics Inc. JUNO Biological Products, (No Disgnostic Substances) (2836) 463656275
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1656998 Robert Azelby C/O 400 Dexter Avenue North
Suite 1200
Seattle WA 98109
Evp & Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-01-17 2,498 $25.29 73,330 No 4 M Direct
Common Stock Acquisiton 2018-01-17 26,633 $20.76 99,963 No 4 M Direct
Common Stock Disposition 2018-01-17 21,141 $68.10 78,822 No 4 S Direct
Common Stock Disposition 2018-01-17 7,990 $69.95 70,832 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2018-01-17 2,498 $0.00 2,498 $25.29
Common Stock Stock Option (Right to Buy) Disposition 2018-01-17 26,633 $0.00 26,633 $20.76
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
30,836 2026-11-07 No 4 M Direct
101,208 2027-02-06 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.
  2. 1/48th of the shares subject to the option vested and became exercisable on December 8, 2016 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter.
  3. 1/48th of the shares subject to the option vested and became exercisable on March 7, 2017 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter.